BRIEF-Zealand Pharma, Roche Enter Collaboration And License Agreement

-0.51%

-1.07%

-1.69%

Dow Jones Industrial Average

DJI

48458.05

-0.51%

S&P 500 index

SPX

6827.41

-1.07%

NASDAQ

IXIC

23195.17

-1.69%

March 12 (Reuters) - Zealand Pharma A/S ZELA.CO:

ZEALAND PHARMA AND ROCHE ENTER COLLABORATION AND LICENSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE PETRELINTIDE AS A FUTURE FOUNDATIONAL THERAPY FOR PEOPLE WITH OVERWEIGHT AND OBESITY
TO RECEIVE $1.65 BILLION IN UPFRONT PAYMENTS
TOTAL CONSIDERATION UP TO $5.3 BILLION
TO PAY ROCHE $350 MILLION FOR CT-388 CONTRIBUTION

Source text: ID:nGNE3hyxW3

Further company coverage: ZELA.CO

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.